NCT01258608 - Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

February 8, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

November 29, 2017

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Mapatumumab

Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.

DRUG

Placebo

Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab

DRUG

Sorafenib

Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.

Trial Locations (43)

15232

GSK Investigational Site, Pittsburgh

19104

GSK Investigational Site, Philadelphia

20246

GSK Investigational Site, Hamburg

30625

GSK Investigational Site, Hanover

38801

GSK Investigational Site, Tupelo

49044

GSK Investigational Site, Dnipropetrovsk

55905

GSK Investigational Site, Rochester

60590

GSK Investigational Site, Frankfurt am Main

61070

GSK Investigational Site, Kharkiv

69032

GSK Investigational Site, Zaporizhia

71103

GSK Investigational Site, Shreveport

79031

GSK Investigational Site, Lviv

80045

GSK Investigational Site, Aurora

81377

GSK Investigational Site, Munich

83092

GSK Investigational Site, Donetsk

88014

GSK Investigational Site, Uzhhorod

115478

GSK Investigational Site, Moscow

125284

GSK Investigational Site, Moscow

150054

GSK Investigational Site, Yaroslavl

194017

GSK Investigational Site, Saint Petersburg

195067

GSK Investigational Site, Moscow

198255

GSK Investigational Site, Saint Petersburg

200385

GSK Investigational Site, Craiova

357502

GSK Investigational Site, Pyatigorsk

400015

GSK Investigational Site, Cluj-Napoca

420029

GSK Investigational Site, Kazan'

620036

GSK Investigational Site, Yekaterinburg

634050

GSK Investigational Site, Tomsk

660133

GSK Investigational Site, Krasnoyarsk

700483

GSK Investigational Site, Iași

07103

GSK Investigational Site, Newark

17033-0850

GSK Investigational Site, Hershey

17033-

GSK Investigational Site, Hershey

80-952

GSK Investigational Site, Gdansk

10-228

GSK Investigational Site, Olsztyn

61-878

GSK Investigational Site, Poznan

71-730

GSK Investigational Site, Szczecin

02-507

GSK Investigational Site, Warsaw

04-125

GSK Investigational Site, Warsaw

00927

GSK Investigational Site, San Juan

022328

GSK Investigational Site, Bucharest

03022

GSK Investigational Site, Kyiv

03039

GSK Investigational Site, Kyiv